|
Post by mnkdfann on Feb 15, 2018 0:58:56 GMT -5
People do leave jobs because they can't stand working for their immediate superior. Case in point: Me. Very true. Also, some love their job but still move around a lot. For new experiences. Or for more pay. Or for a new challenge. Kendall, great as he is, appears to love to move around (to be charitable, I'm assuming he was the one who always decided when to leave). He's had at least 8 different jobs, and at least 6 different employers, in about 2 decades.
|
|
|
Post by babaoriley on Feb 15, 2018 1:40:18 GMT -5
Will it be a pump or the real thing? I guess if it’s a planned sale like last October then it’s a planned pump and I hopefully would be smart enough to sell. Then rebuy after the dump. No, no, KC, this time it's different, this time is different!!
|
|
|
Post by babaoriley on Feb 15, 2018 1:42:47 GMT -5
I will take another pump - So I can dump....and pop back in with more shares after the dust settles. Which it will IMO. Fool me once...... I am long 1600 shares too looking for a pop. Long 1600 and short how many, TD?
|
|
|
Post by #NoMoreNeedles on Feb 15, 2018 4:29:28 GMT -5
Let's wait for the next announcements: International expansion, RLS, etc.
|
|
|
Post by falconquest on Feb 15, 2018 7:03:37 GMT -5
Recent activity, i.e. Dr. Kendall, Deerfield, new sales team members being added and pps movement, remains a big puzzle with a key piece or two still missing. IMO, Mike C and team are holding the missing piece close to the vest but used it to entice Dr. Kendall to jump ship from Lilly and join Mannkind. A swag guess is that it has to do with knowledge of the STAT study results and forthcoming plans for new and much stronger TV ads. This could also be used to raise funds by enticing a major player that first wanted Deerfield out. This would be easy for a cash strong BP to pull off since Deerfield's not really in the business to invest and hold anyway. Mike also knows a bigger sales force is needed and said months ago that he wanted one or more partners. This would also explain why Mike felt comfortable enough to boldly critique insurance. I have confidence Mike knows how to play the game. Just my guess. Anyone can play. I sure hope Mike knows a lot more about deals soon to be announce or I among others will be very very sad. As far as Dr. Kendall, he has been following afrezza for years. Al Mann knew everyone in the diabetes community and when someone like Al plows $1B of his own money into it either the guy lost his marbles or he really had something. That crazy old guy had a whistle in his pocket everywhere he went. The first trials started about 10 years ago. Al ran over 60. Mike made reference in a recent video interview saying "over 50". It was never clear to me until recently Mike was aware of all the studies. Clearly he did not read or understand them as he also made reference to Alan Marcus talking about alpha cells being blocked which was based on the 118 trial. At this point I would be shocked if Dr. Kendal has not reviewed in detail each of those studies. IMO, nothing which Al Mann did not already know is going to come out of the STAT study. There is only one thing which allows the cells to use the glucose in the blood and thats insulin. Add it at meals and stop the spike along with the CGM and its a slam dunk. While the "Medical Community" may be shocked by the STAT results I doubt most on this board will be and Dr. Kendall will not be. You want the reason for the rise since last week, one name, Dr. David Kendall. He restores the credibility to Mannkind it lost two years ago and because of his "youth" and positive relationships in the community he probably takes MNKD's credibility beyond what it was with Al. With Dr. Kendall, Mannkind is not only back in the game they could have become the favorite in the game. What's that worth in pps? It sure is not $4 in a $60B market. So your thesis begs the question; If Al knew Dr. Kendall and believed he could swing the pendulum then why wasn't he hired years ago? One could argue that Castagna has a broader deal in the works that mollifies any reservation Dr. Kendall may have had or perhaps it is just that timing was right. We can't really know. Were I Al, I would have brought him on board much much sooner. Then again, none of us have ever been able to figure out this company as it always keeps us guessing.
|
|
|
Post by sayhey24 on Feb 15, 2018 7:47:17 GMT -5
At least two reasons.
10 years ago the incretin drugs showed huge promise. In fact Ralph DeFronzo is having great success in his ongoing Qatar Study at stopping the progression of T2. Given the choice seven years ago of getting the huge office, huge salary and bragging rights going to work at Lilly, I probably would have done the same thing. However there is more.
At the same time Pfizer came to market with Exubera but was seeing afrezza in the rear view mirror as a far superior product on the verge of approval. The chief scientist on the Exubera project told me they knew everything about afrezza and Pfizer knew it would take the market. Pfizer made the decision to not make the market for afrezza but rather pull Exubera and poison the market with the cancer FUD. What reasonable diabetes expert who is not emotionally attached to afrezza is going to go out on a limb and take a job with MNKD when Lilly is offering a HUGE deal? Not me and not Kendall.
Take the time and go back to the ADCOM videos. The two big question; why not a huge change in A1c; and whats the long term lung impacts. The first is easy to answer but the second would take time.
Now its 2018 and the first afrezza trials started 10 years ago. There are still some using afrezza for that period and no issues. In fact I think one lady tracked Mike down not long ago and said how its changed her life and guess what, no lung issues. We have had three years since product approval and guess what, in general no lung issues.
At the same time 10 years later and the incretins have turned out exactly like Al Mann predicted, causing bigger issues than they are solving. I have no idea what Dr. Kendall has seen at Lilly with Trulicity. What I do know is as bad as Byetta and the rest are Trulicity may be even worse, if thats possible. It already comes with an FDA ‘black box’ warning about its risks of medullary thyroid cancer and other thyroid tumours. It was approved on the basis of just five small clinical trials (less than is usual for this kind of drug). The FDA has required the Eli Lilly to carry out five ‘post-marketing studies’, including an assessment of cardiovascular risks in people with type 2 diabetes as there is concern it may cause heart attacks too. Would I want to be associated with that???
With Dr. Kendall at this point in his career I don't think its about the money. I think he wants to do good for PWDs of the world. I think he is more of the cut of Al Mann and many here on Proboards. Would we like MNKD stock to go to $500, sure. But as Al said take care of the PWD and the rest will come. I would say Dr. David Kendall has now become a full-fledged member of the afrezza club.
|
|
|
Post by peppy on Feb 15, 2018 7:58:01 GMT -5
At least two reasons. 10 years ago the incretin drugs showed huge promise. In fact Ralph DeFronzo is having great success in his ongoing Qatar Study at stopping the progression of T2. Given the choice seven years ago of getting the huge office, huge salary and bragging rights going to work at Lilly, I probably would have done the same thing. However there is more. At the same time Pfizer came to market with Exubera but was seeing afrezza in the rear view mirror as a far superior product on the verge of approval. The chief scientist on the Exubera project told me they knew everything about afrezza and Pfizer knew it would take the market. Pfizer made the decision to not make the market for afrezza but rather pull Exubera and poison the market with the cancer FUD. What reasonable diabetes expert who is not emotionally attached to afrezza is going to go out on a limb and take a job with MNKD when Lilly is offering a HUGE deal? Not me and not Kendall. Take the time and go back to the ADCOM videos. The two big question; why not a huge change in A1c; and whats the long term lung impacts. The first is easy to answer but the second would take time. Now its 2018 and the first afrezza trials started 10 years ago. There are still some using afrezza for that period and no issues. In fact I think one lady tracked Mike down not long ago and said how its changed her life and guess what, no lung issues. We have had three years since product approval and guess what, in general no lung issues. At the same time 10 years later and the incretins have turned out exactly like Al Mann predicted, causing bigger issues than they are solving. I have no idea what Dr. Kendall has seen at Lilly with Trulicity. What I do know is as bad as Byetta and the rest are Trulicity may be even worse, if thats possible. It already comes with an FDA ‘black box’ warning about its risks of medullary thyroid cancer and other thyroid tumours. It was approved on the basis of just five small clinical trials (less than is usual for this kind of drug). The FDA has required the Eli Lilly to carry out five ‘post-marketing studies’, including an assessment of cardiovascular risks in people with type 2 diabetes as there is concern it may cause heart attacks too. Would I want to be associated with that??? With Dr. Kendall at this point in his career I don't think its about the money. I think he wants to do good for PWDs of the world. I think he is more of the cut of Al Mann and many here on Proboards. Would we like MNKD stock to go to $500, sure. But as Al said take care of the PWD and the rest will come. I would say Dr. David Kendall has now become a full-fledged member of the afrezza club. yeah yeah.
|
|
|
Post by traderdennis on Feb 15, 2018 9:16:32 GMT -5
I am long 1600 shares too looking for a pop. Long 1600 and short how many, TD? If I go short I don’t go longer than a few hours.
|
|
|
Post by dh4mizzou on Feb 15, 2018 9:20:19 GMT -5
No worries. If this had any possibility at all, Mike C would have disclosed this to Dr. Kendall and he would have NEVER left Lilly. Dr. Kendall joining Mannkind is "almost" proof that Mike has something up his sleeve. People do leave jobs because they can't stand working for their immediate superior. Case in point: Me.
Just curious. How many people have you run off?
|
|
|
Post by kc on Feb 15, 2018 10:09:32 GMT -5
I would bet that Kendall knows too well what Afrezza is about and has talked to his fellow research friends JDRF President Dr. Aaron Kowalski and folks like Dr. Steven Edelman who both are users and encouraged him to take the leap as Afrezza is really a unique Insulin that works well. He didn't leave Lilly to go to a failing company. Something is up. There is a clearer path to success that we see today.
|
|
|
Post by matt on Feb 15, 2018 10:24:15 GMT -5
People do leave jobs because they can't stand working for their immediate superior. Case in point: Me. Also, some love their job but still move around a lot. For new experiences. Or for more pay. Or for a new challenge. Lilly is a company in transition, like much of pharma. He might well have looked around at the diabetes business and decided it was not going to be an interesting place to work in the coming years. Likewise, he may have look around Lilly to test whether he had a good chance to jumping to a different therapeutic area or whether there were too many strong candidates with better resumes. Ultimately, the best way to get a job as a medical director at any pharma company is to have been the medical director at a pharma company. Many clients specify to the recruiter that they want to hire executives with a specific experience and being number two, even in a great organization, does not get you the interview. If he comes to MNKD and the company does well, then he makes our very well on his incentive compensation. If MNKD does not do well and he decides to move on, he now gets to interview for the top job at other companies, and the top job at most biotechs tends to pay more than what a division executive will be making at Lilly. It is not a bad bet for him to make.
|
|
|
Post by peppy on Feb 15, 2018 10:37:22 GMT -5
Also, some love their job but still move around a lot. For new experiences. Or for more pay. Or for a new challenge. Lilly is a company in transition, like much of pharma. He might well have looked around at the diabetes business and decided it was not going to be an interesting place to work in the coming years. Likewise, he may have look around Lilly to test whether he had a good chance to jumping to a different therapeutic area or whether there were too many strong candidates with better resumes. Ultimately, the best way to get a job as a medical director at any pharma company is to have been the medical director at a pharma company. Many clients specify to the recruiter that they want to hire executives with a specific experience and being number two, even in a great organization, does not get you the interview. If he comes to MNKD and the company does well, then he makes our very well on his incentive compensation. If MNKD does not do well and he decides to move on, he now gets to interview for the top job at other companies, and the top job at most biotechs tends to pay more than what a division executive will be making at Lilly. It is not a bad bet for him to make. oh.... I thought perhaps he had been visited by the ghost of Christmas past, present and future and decided to do the right thing. Love your numbers, miss your legs.
|
|
|
Post by kite on Feb 15, 2018 10:45:41 GMT -5
Lilly is a company in transition, like much of pharma. He might well have looked around at the diabetes business and decided it was not going to be an interesting place to work in the coming years. Likewise, he may have look around Lilly to test whether he had a good chance to jumping to a different therapeutic area or whether there were too many strong candidates with better resumes. Ultimately, the best way to get a job as a medical director at any pharma company is to have been the medical director at a pharma company. Many clients specify to the recruiter that they want to hire executives with a specific experience and being number two, even in a great organization, does not get you the interview. If he comes to MNKD and the company does well, then he makes our very well on his incentive compensation. If MNKD does not do well and he decides to move on, he now gets to interview for the top job at other companies, and the top job at most biotechs tends to pay more than what a division executive will be making at Lilly. It is not a bad bet for him to make. oh.... I thought perhaps he had been visited by the ghost of Christmas past, present and future and decided to do the right thing. Love your numbers, miss your legs. Funny, I'm listening to Christmas music right now by The Piano Guys... not joking
|
|
|
Post by peppy on Feb 15, 2018 12:51:23 GMT -5
|
|
|
Post by sayhey24 on Feb 15, 2018 13:43:09 GMT -5
Peppy - I think you nailed it. How do you live with yourself after seeing all the amputations now happening and MRK just got another SGLT-2 approved Whats Kendall now say knowing what we know now. Maybe Good Grief what was I thinking? “Cardiovascular disease remains the leading cause of death in people with type 2 diabetes and contributes significantly to the burden of diabetes care,” said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes. “The results presented at EASD add further evidence of the benefit Jardiance can provide to adults with type 2 diabetes with different background blood sugar control.” www.boehringer-ingelheim.us/press-release/jardiance-empagliflozin-tablets-reduced-risk-cardiovascular-death-people-type-2
|
|